News >

Isatuximab Nears European Approval for Relapsed/Refractory Myeloma

Jason M. Broderick @jasoncology
Published: Friday, Mar 27, 2020

John Reed, MD, PhD

John Reed, MD, PhD

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥2 prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor and have demonstrated disease progression on the last therapy.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication